PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 5:09 AM ET

Sponsor Check › Person

JS
No photo found yet (own website and image search run after this page is viewed)

Jonathan T. Silverstein

Named as an officer, director or promoter on SEC Form D filings · NY, Quebec, Canada (as filed: A8), CA, NJ, CO, MA, IL · Dec 30, 2009 → Dec 10, 2021

33deals (issuers)
$7.27Breported sold
1,930investors
104Form D filings
2009–2021years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:17 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Jonathan T. Silverstein is listed as an executive officer, director, and promoter on 104 SEC Form D filings by 33 issuers between Mar 2009 and Jul 2024. Largest by amount reported sold: OrbiMed Partners II, L.P. (New York, NY — pooled investment fund — 2011–2021; $1.78B reported sold to 880 investors), OrbiMed Royalty Opportunities II, LP (New York, NY — pooled investment fund — 2015; $900M reported sold to 83 investors), OrbiMed Royalty & Credit Opportunities III, LP (New York, NY — pooled investment fund — 2019; $889.8M reported sold to 69 investors), OrbiMed Private Investments V, LP (New York, NY — pooled investment fund — 2013; $699.5M reported sold to 66 investors), OrbiMed Asia Partners III, L.P. (New York, NY — pooled investment fund — 2017; $540M reported sold to 97 investors) and 28 more (all listed below).

What this means That is a lot of deals — 33 separate companies raised money with this person listed as executive officer, director, and promoter, over about 15 years. Across those companies the filings report $7.27B sold in total.

Listed alongside Carl L. Gordon (63 shared filings), W. Carter Neild (58 shared filings), Sven H. Borho (55 shared filings), OrbiMed Advisors LLC (50 shared filings, management entity), Geoffrey C. Hsu (49 shared filings) and 166 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jonathan. Each name links to their own page.

The issuers belong to 3 sponsor groups: Orbimed (37 issuers, $20.2B reported sold, 2009–2026), Rhythm Pharmaceuticals (3 issuers, $54M reported sold, 2010–2017) and Group linked by Olav B. Bergheim (14 issuers, $144.9M reported sold, 2008–2025).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 2 bankruptcy cases matching the name listed in Key records below.

What this means 2 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared the newest 50 of 104 public filings for Jonathan T. Silverstein and found 19 differences, 4 worth asking the sponsor about: 4 Form Ds were filed more than 15 days after the first sale; Jonathan T. Silverstein is no longer listed on the Dec 9, 2022 amendment; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Jonathan T. Silverstein has not run yet — it is #4,559 of 8,317 in line; searches run around the clock at the hosts' allowed rate. Searched so far: 27 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:17 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Jonathan T. Silverstein..

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

2 cases: 2 closed (disposition not in docket feed)

Jonathan Silverstein and Jennifer Silverstein closed
United States Bankruptcy Court, S.D. New York · No. 19-13737 · Filed Nov 20, 2019 · Closed Mar 20, 2020
Role of Jonathan Silverstein and Jennifer Silverstein: Debtor · Outcome: Case closed 2020-03-20 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (rare in federal dockets); 4 people with this name in Form D filings; court in the person's filing state (NY); middle initial differs
Jonathan G. Silverstein and Paula M. Herrmann closed
United States Bankruptcy Court, N.D. Illinois · No. 13-36331 · Filed Sep 13, 2013 · Closed Feb 6, 2019
Role of Jonathan G. Silverstein and Paula M. Herrmann: Debtor · Outcome: Case closed 2019-02-06 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (rare in federal dockets); 4 people with this name in Form D filings; court in the person's filing state (IL); middle initial differs
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:17 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

19 differences found between the filings for Jonathan T. Silverstein — 4 worth asking about (compared the newest 50 of 104 filings on Oct 24, 2026; older filings not covered)

Worth asking · Sep 20, 2019 – Jul 5, 2024

4 Form Ds were filed more than 15 days after the first sale

Form D filed 141 days after the first sale — VANQUA BIO, INC. · Form D filed 19 days after the first sale — VANQUA BIO, INC. · Form D filed 35 days after the first sale — OrbiMed Genesis Fund, L.P. · Form D filed 17 days after the first sale — VANQUA BIO, INC.

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Jul 5, 2024 ↗VANQUA BIO, INC. — PartnerFacts page ↗Form D · Sep 15, 2021 ↗Form D · Dec 12, 2019 ↗
Sources
Worth asking · Dec 10, 2021 – Dec 9, 2022

Jonathan T. Silverstein is no longer listed on the Dec 9, 2022 amendment — OrbiMed Genesis Fund, L.P.

Jonathan T. Silverstein appears on the Dec 10, 2021 Form D/A (executive officer) but not on the Dec 9, 2022 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D/A · Dec 10, 2021 ↗Form D/A · Dec 9, 2022 ↗Jonathan T. Silverstein — PartnerFacts page ↗OrbiMed Genesis Fund, L.P. — PartnerFacts page ↗
Sources
Worth asking · Jul 16, 2021 – Jul 14, 2022

Jonathan T. Silverstein is no longer listed on the Jul 14, 2022 amendment — OrbiMed Partners II, L.P.

Jonathan T. Silverstein appears on the Jul 16, 2021 Form D/A (executive officer) but not on the Jul 14, 2022 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D/A · Jul 16, 2021 ↗Form D/A · Jul 14, 2022 ↗Jonathan T. Silverstein — PartnerFacts page ↗OrbiMed Partners II, L.P. — PartnerFacts page ↗
Sources
Worth asking · Apr 14, 2021 – Apr 14, 2022

Jonathan T. Silverstein is no longer listed on the Apr 14, 2022 amendment — OrbiMed New Horizons Fund, L.P.

Jonathan T. Silverstein appears on the Apr 14, 2021 Form D/A (executive officer) but not on the Apr 14, 2022 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D/A · Apr 14, 2021 ↗Form D/A · Apr 14, 2022 ↗Jonathan T. Silverstein — PartnerFacts page ↗OrbiMed New Horizons Fund, L.P. — PartnerFacts page ↗
Sources
Note · Oct 7, 2019 – Sep 15, 2021

Jonathan T. Silverstein's role changed at VANQUA BIO, INC.: executive officer, director → director

The Oct 7, 2019 filing lists Jonathan T. Silverstein as executive officer, director; the Sep 15, 2021 Form D lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Oct 7, 2019 ↗Form D · Sep 15, 2021 ↗Jonathan T. Silverstein — PartnerFacts page ↗VANQUA BIO, INC. — PartnerFacts page ↗
Sources
Note · Jul 14, 2014 – Jul 14, 2015

Jonathan T. Silverstein's role changed at OrbiMed Partners II, L.P.: executive officer, promoter → executive officer

The Jul 14, 2014 filing lists Jonathan T. Silverstein as executive officer, promoter; the Jul 14, 2015 Form D/A lists executive officer.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D/A · Jul 14, 2014 ↗Form D/A · Jul 14, 2015 ↗Jonathan T. Silverstein — PartnerFacts page ↗OrbiMed Partners II, L.P. — PartnerFacts page ↗
Sources
Note · Jul 14, 2014 – Jul 14, 2015

Jonathan T. Silverstein's role changed at OrbiMed Partners, L.P.: executive officer, promoter → executive officer

The Jul 14, 2014 filing lists Jonathan T. Silverstein as executive officer, promoter; the Jul 14, 2015 Form D/A lists executive officer.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D/A · Jul 14, 2014 ↗Form D/A · Jul 14, 2015 ↗Jonathan T. Silverstein — PartnerFacts page ↗OrbiMed Partners, L.P. — PartnerFacts page ↗
Sources
Note · Jun 28, 2017 – Sep 6, 2017

Offering amount changed between filings — OrbiMed Asia Partners III, L.P.

The Jun 28, 2017 filing says $450,000,000 offered; the Sep 6, 2017 Form D/A says $539,960,000.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D/A (earlier) · Jun 28, 2017 ↗Form D/A (later) · Sep 6, 2017 ↗OrbiMed Asia Partners III, L.P. — PartnerFacts page ↗
Sources
Note · Jan 9, 2017 – Aug 8, 2017

Offering amount changed between filings — NeuroPace Inc

The Jan 9, 2017 filing says $50,000,000 offered; the Aug 8, 2017 Form D/A says $80,000,001.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Jan 9, 2017 ↗Form D/A (later) · Aug 8, 2017 ↗NeuroPace Inc — PartnerFacts page ↗
Sources
Note · Aug 26, 2015 – Jan 27, 2016

Offering amount changed between filings — Adicet Bio, Inc.

The Aug 26, 2015 filing says $40,000,000 offered; the Jan 27, 2016 Form D/A says $43,318,510.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Aug 26, 2015 ↗Form D/A (later) · Jan 27, 2016 ↗Adicet Bio, Inc. — PartnerFacts page ↗
Sources
Note · Jan 1, 1993 – Jul 16, 2021

12 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — OrbiMed Global Healthcare Fund, L.P. (latest filing Jul 16, 2021) · No amendment in the last 12 months on an offering that may still be open — OrbiMed Global Healthcare Associates Fund, L.P. (latest filing Jul 16, 2021) · No amendment in the last 12 months on an offering that may still be open — OrbiMed Asia Partners IV, L.P. (latest filing Sep 2, 2020) · No amendment in the last 12 months on an offering that may still be open — Arcutis Biotherapeutics, Inc. (latest filing Oct 22, 2019) · No amendment in the last 12 months on an offering that may still be open — VANQUA BIO, INC. (latest filing Oct 7, 2019) · and 7 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D/A · Jul 16, 2021 ↗OrbiMed Global Healthcare Fund, L.P. — PartnerFacts page ↗Form D/A · Jul 16, 2021 ↗OrbiMed Global Healthcare Associates Fund, L.P. — PartnerFacts page ↗
Sources
Note · Mar 11, 2011 – Aug 26, 2015

Jonathan T. Silverstein is written 2 different ways on the filings

listed as "Jonathan T. Silverstein" on 53 filings (from Mar 11, 2011), and "Jonathan Silverstein" on 15 filings (from Aug 26, 2015).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D/A · Mar 11, 2011 ↗Form D · Aug 26, 2015 ↗Jonathan T. Silverstein — PartnerFacts page ↗
Sources
Note · Oct 7, 2019 – Sep 15, 2021

Industry group changed between filings — VANQUA BIO, INC.

"Other Technology" (Oct 7, 2019); then "Biotechnology" (Sep 15, 2021 to Jul 5, 2024).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Oct 7, 2019 ↗Form D · Sep 15, 2021 ↗VANQUA BIO, INC. — PartnerFacts page ↗
Sources
Note · Sep 5, 2017

Same name, different state: "Jonathan Silverstein" (TX) is a separate record

This page covers filings where the address state is NY or A8 or CA or NJ or CO or MA or IL. A separate record, "Jonathan Silverstein" with address state TX, is listed on 1 filing — most recently by Springbox Labs, Inc. (Sep 5, 2017). Both records have filings in the same period (Sep 5, 2017).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Jonathan Silverstein (TX) — PartnerFacts page ↗Form D · Sep 5, 2017 ↗Springbox Labs, Inc. — PartnerFacts page ↗Jonathan T. Silverstein (NY,A8,CA,NJ,CO,MA,IL) — this page ↗
Sources
Note · Dec 9, 2014

Same name, different state: "Jonathan Silverstein" (G7) is a separate record

This page covers filings where the address state is NY or A8 or CA or NJ or CO or MA or IL. A separate record, "Jonathan Silverstein" with address state G7, is listed on 1 filing — most recently by Ascendis Pharma A/S (Dec 9, 2014). Both records have filings in the same period (Dec 9, 2014).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Jonathan Silverstein (G7) — PartnerFacts page ↗Form D · Dec 9, 2014 ↗Ascendis Pharma A/S — PartnerFacts page ↗Jonathan T. Silverstein (NY,A8,CA,NJ,CO,MA,IL) — this page ↗
Sources
Note · Aug 26, 2015 – Jan 27, 2016

Address moved from New York, NY to Menlo Park, CA — Adicet Bio, Inc.

The people listed on the Aug 26, 2015 filing give New York, NY; on the Jan 27, 2016 filing they give Menlo Park, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Aug 26, 2015 ↗Form D · Jan 27, 2016 ↗Adicet Bio, Inc. — PartnerFacts page ↗
Sources
Note · Mar 11, 2011 – Jul 5, 2024

Jonathan T. Silverstein is listed with 6 different address states: NY, CA, CO, NJ, MA, IL

NY on 56 filings (Mar 11, 2011 to Dec 10, 2021); CA on 5 filings (Jan 27, 2016 to Oct 22, 2019); CO on 1 filing (Sep 26, 2016); NJ on 1 filing (Sep 30, 2016); MA on 3 filings (Jan 6, 2017 to May 11, 2018); IL on 2 filings (Sep 15, 2021 to Jul 5, 2024).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D/A · Mar 11, 2011 ↗Form D/A · Jan 27, 2016 ↗Form D · Sep 26, 2016 ↗Form D · Sep 30, 2016 ↗
Sources
Note · Apr 14, 2020 – Apr 14, 2021

Reported net asset value range changed between filings — OrbiMed New Horizons Fund, L.P.

"$25,000,001 - $50,000,000" (Apr 14, 2020); then "Decline to Disclose" (Apr 14, 2021).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · Apr 14, 2020 ↗Form D/A · Apr 14, 2021 ↗OrbiMed New Horizons Fund, L.P. — PartnerFacts page ↗
Sources
Note · Jun 28, 2017 – Sep 6, 2017

Minimum investment changed between filings — OrbiMed Asia Partners III, L.P.

The Jun 28, 2017 filing lists a minimum of $0; the Sep 6, 2017 Form D/A lists $100,000.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D/A (earlier) · Jun 28, 2017 ↗Form D/A (later) · Sep 6, 2017 ↗OrbiMed Asia Partners III, L.P. — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. We compared the newest 50 of 104 filings (work cap); older filings are not covered here. As of Oct 24, 2026.

5. Money to insiders

10 of 55 offerings report sales commissions totalling $46,505,682; 0 report finder's fees; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jul 5, 2024 D
VANQUA BIO, INC.
File 021-517876
$0$0$0None listed on this filingEDGAR ↗
Dec 10, 2021 D/A
OrbiMed Genesis Fund, L.P.
File 021-355430
$0$0$0
The fund charges a management fee that is described in the fund's offering documents.
None listed on this filingEDGAR ↗
Sep 15, 2021 D
VANQUA BIO, INC.
File 021-413372
$0$0$0None listed on this filingEDGAR ↗
Jul 16, 2021 D/A
OrbiMed Partners II, L.P.
File 021-128771
$30,728,808 (est.)$0$0
The fund charges a management fee that is described in the fund's offering documents.
Far Hills Group, LLC BrokerCheck CRD 32243 ↗
J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗		EDGAR ↗
Jul 16, 2021 D/A
OrbiMed Global Healthcare Associates Fund, L.P.
File 021-212193
$0$0$0None listed on this filingEDGAR ↗
Jul 16, 2021 D/A
OrbiMed Global Healthcare Fund, L.P.
File 021-220964
$0$0$0
The fund charges a management fee that is described in the fund's offering documents.
None listed on this filingEDGAR ↗
Apr 14, 2021 D/A
OrbiMed New Horizons Fund, L.P.
File 021-364898
$0$0$0
The fund charges a management fee that is described in the fund's offering documents.
None listed on this filingEDGAR ↗
Sep 2, 2020 D/A
OrbiMed Asia Partners IV, L.P.
File 021-362067
$0 (est.)$0 (est.)$0 (est.)
An affiliate of the GPLP and GPLTD will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter.
J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗EDGAR ↗
Aug 27, 2020 D
OrbiMed Private Investments VIII, LP
File 021-374300
$0$0$0
An affiliate of the General Partner will receive a fee for management services equal to a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter.
None listed on this filingEDGAR ↗
Oct 22, 2019 D
Arcutis Biotherapeutics, Inc.
File 021-351627
$0$0$0None listed on this filingEDGAR ↗
Oct 7, 2019 D
VANQUA BIO, INC.
File 021-350518
$0$0$0None listed on this filingEDGAR ↗
Jul 3, 2019 D/A
OrbiMed Royalty & Credit Opportunities III, LP
File 021-331673
$0 (est.)$0 (est.)$0 (est.)
An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter.
J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗EDGAR ↗
Oct 26, 2018 D/A
Adicet Bio, Inc.
File 021-246441
$0$0$0None listed on this filingEDGAR ↗
May 11, 2018 D
AVEDRO INC
File 021-312182
$0$0$0None listed on this filingEDGAR ↗
Jan 30, 2018 D
OrbiMed Private Investments VII, LP
File 021-304413
$0$0$0 (est.)
An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter.
None listed on this filingEDGAR ↗
Sep 6, 2017 D/A
OrbiMed Asia Partners III, L.P.
File 021-281414
$2,478,300$0$0 (est.)
An affiliate of the GPLP will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage based on invested capital thereafter.
J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗EDGAR ↗
Aug 8, 2017 D/A
NeuroPace Inc
File 021-277965
$0$0$0 (est.)
Proceeds will be used for general corporate purposes including, but not limited to, executive salaries
None listed on this filingEDGAR ↗
Jul 14, 2017 D/A
OrbiMed Partners, L.P.
File 021-91544-4N
$3,228,724 (est.)$0$0
The fund charges a management fee that is described in the fund's offering documents.
Far Hills Group, LLC BrokerCheck CRD 32243 ↗EDGAR ↗
May 1, 2017 D
AVEDRO INC
File 021-285796
$0$0$0None listed on this filingEDGAR ↗
Jan 20, 2017 D
RHYTHM PHARMACEUTICALS, INC.
File 021-278910
$0$0$0None listed on this filingEDGAR ↗
Jan 6, 2017 D
scPharmaceuticals Inc.
File 021-277857
$0$0$0None listed on this filingEDGAR ↗
Sep 30, 2016 D
Roka BioScience, Inc.
File 021-271657
$949,850$0$0 (est.)
The proceeds are expected to be used for general corporate purposes which may include the payment of salaries and other fees to those listed in Item 3.
Roth Capital Partners, LLC BrokerCheck CRD 15407 ↗EDGAR ↗
Sep 26, 2016 D
CERAPEDICS INC
File 021-271250
$500,000$0$0Leerink Partners LLC BrokerCheck CRD 39011 ↗EDGAR ↗
Jan 27, 2016 D
Adicet Bio, Inc.
File 021-256078
$0$0$0None listed on this filingEDGAR ↗
Dec 14, 2015 D
OrbiMed Israel Partners II, L.P.
File 021-253036
$0$0$0 (est.)
An affiliate of the GPLP will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter.
None listed on this filingEDGAR ↗
Dec 10, 2015 D/A
RHYTHM PHARMACEUTICALS, INC.
File 021-245580
$0$0$0None listed on this filingEDGAR ↗
Oct 22, 2015 D
Audentes Therapeutics, Inc.
File 021-249874
$0$0$0None listed on this filingEDGAR ↗
Sep 15, 2015 D
OrbiMed Private Investments VI, LP
File 021-247616
$0$0$0 (est.)
An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter.
None listed on this filingEDGAR ↗
Sep 2, 2015 D
Audentes Therapeutics, Inc.
File 021-246838
$0$0$0None listed on this filingEDGAR ↗
Feb 23, 2015 D
CERAPEDICS INC
File 021-234532
$0$0$0None listed on this filingEDGAR ↗
Feb 2, 2015 D
OrbiMed Royalty Opportunities II, LP
File 021-233267
$1,500,000$0$0 (est.)
An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter.
Merrill Lynch, Pierce, Fenner & Smith Incorporated BrokerCheck CRD 7691 ↗EDGAR ↗
Dec 24, 2014 D
Audentes Therapeutics, Inc.
File 021-230835
$0$0$0None listed on this filingEDGAR ↗
Dec 31, 2013 D
DFINE INC
File 021-209047
$0$0$0None listed on this filingEDGAR ↗
Dec 5, 2013 D
Roka BioScience, Inc.
File 021-207477
$0$0$0 (est.)
A portion of the proceeds may be used for general corporate purposes. Salaries and/or director fees may be paid to certain related persons in Item 3. The amount of such fees cannot be determined as this time.
None listed on this filingEDGAR ↗
Nov 5, 2013 D
OrbiMed Private Investments V, LP
File 021-205773
$1,740,000 (est.)$0$0 (est.)
An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter.
Merrill Lynch, Pierce, Fenner & Smith Incorporated BrokerCheck CRD 7691 ↗EDGAR ↗
Aug 15, 2013 D
OrbiMed Asia Partners II, LP
File 021-201444
$0 (est.)$0$0 (est.)
An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter.
Merrill Lynch, Pierce, Fenner & Smith Incorporated BrokerCheck CRD 7691 ↗EDGAR ↗
Jun 27, 2013 D
Roka BioScience, Inc.
File 021-198730
$0 (est.)$0 (est.)$0 (est.)
A portion of the proceeds may be used for general corporate purposes. Salaries and/or director fees may be paid to certain related persons in Item 3. The amount of such fees cannot be determined as this time.
None listed on this filingEDGAR ↗
Jan 25, 2013 D
GLAUKOS Corp
File 021-190823
$0$0$0None listed on this filingEDGAR ↗
Dec 11, 2012 D/A
Relypsa Inc
File 021-182532
$0$0$0None listed on this filingEDGAR ↗
Nov 27, 2012 D/A
CERAPEDICS INC
File 021-181546
$0$0$0None listed on this filingEDGAR ↗
Oct 3, 2012 D
GLAUKOS Corp
File 021-184931
$0$0$0None listed on this filingEDGAR ↗
Sep 4, 2012 D/A
INTERCEPT PHARMACEUTICALS INC
File 021-183201
$0$0$0None listed on this filingEDGAR ↗
Aug 10, 2012 D
GLAUKOS Corp
File 021-182573
$0$0$0None listed on this filingEDGAR ↗
Feb 16, 2012 D
CERAPEDICS INC
File 021-173576
$0$0$0None listed on this filingEDGAR ↗
Oct 5, 2011 D
DFINE INC
File 021-166773
$0$0$0None listed on this filingEDGAR ↗
Aug 24, 2011 D
Enobia Pharma Corp
File 021-164842
$1,300,000 (est.)$0$0
The net proceeds of the offering will be used for general corporate and working capital purposes, a portion of which may be applied to pay executive officers and directors.
None listed on this filingEDGAR ↗
Aug 8, 2011 D/A
Relypsa Inc
File 021-147705
$0$0$0None listed on this filingEDGAR ↗
Apr 18, 2011 D
OrbiMed Israel Partners Limited Partnership
File 021-158558
$1,830,000 (est.)$0$0 (est.)
An affiliate of the General Partner will receive an annual fee for management services. Amount to be paid, number of years to be paid and extent paid out of adjusted gross proceeds are unknown at this time
J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗EDGAR ↗
Apr 1, 2011 D
Enobia Pharma Corp
File 021-157715
$0$0$0
Proceeds are applied to general corporate and working capital purposes, a portion of which may be applied to pay executive officers and directors.
None listed on this filingEDGAR ↗
Feb 1, 2011 D
GLAUKOS Corp
File 021-154689
$0$0$0None listed on this filingEDGAR ↗
Dec 13, 2010 D/A
Enobia Pharma Corp
File 021-109028
$0$0$0
Proceeds are applied to general corporate and working capital purposes, a portion of which may be applied to pay executive officers and directors.
None listed on this filingEDGAR ↗
Sep 23, 2010 D
GLAUKOS Corp
File 021-148086
$0$0$0None listed on this filingEDGAR ↗
Jul 15, 2010 D
DFINE INC
File 021-145053
$0$0$0None listed on this filingEDGAR ↗
Dec 30, 2009 D
Caduceus Private Investments IV, LP
File 021-137285
$2,250,000 (est.)$0$0 (est.)
An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of the aggregate subscriptions of the Issuer's limited partners during the investment period, and a percentage of invested capital thereafter.
J.P. Morgan Securities Inc. BrokerCheck CRD 79 ↗EDGAR ↗
Mar 30, 2009 D
CERAPEDICS INC
File 021-101063
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 33

Every issuer that named Jonathan T. Silverstein on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

VB
Biotechnology · group: Orbimed

VANQUA BIO, INC.

Chicago, IL · Oct 7, 2019 → Jul 5, 2024 · 3 filings
  • Jul 5, 2024 · D · $44,979,987 sold of $44,979,987 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 15, 2021 · D · $84,999,987 sold of $84,999,987 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 7, 2019 · D · $6,000,000 sold of $18,000,000 · 1 investors · min. No minimum reported · role: Executive Officer, Director (President & Director) EDGAR ↗

Raised $85M from 12 investors (100% of the $45M target) as of the latest filing. Jonathan is listed as director, executive officer on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OG
Pooled Investment Fund · group: Orbimed

OrbiMed Genesis Fund, L.P.

New York, NY · Dec 12, 2019 → Dec 10, 2021 · 3 filings
  • Dec 10, 2021 · D/A · $184,125,000 sold of Indefinite · 64 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Dec 11, 2020 · D/A · $59,275,000 sold of Indefinite · 24 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Dec 12, 2019 · D · $50,100,000 sold of Indefinite · 15 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗

Raised $353.3M from 107 investors as of the latest filing. Jonathan is listed as executive officer on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OP
Pooled Investment Fund · group: Orbimed

OrbiMed Partners II, L.P.

New York, NY · Mar 11, 2011 → Jul 16, 2021 · 12 filings
  • Jul 16, 2021 · D/A · $1,770,099,650 sold of Indefinite · 874 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗
  • Jul 16, 2020 · D/A · $1,749,614,118 sold of Indefinite · 849 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗
  • Jul 16, 2019 · D/A · $1,738,864,013 sold of Indefinite · 842 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗
  • Jul 16, 2018 · D/A · $1,714,214,013 sold of Indefinite · 835 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗
  • Jul 14, 2017 · D/A · $1,643,696,853 sold of Indefinite · 797 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗
  • Jul 14, 2016 · D/A · $1,565,361,853 sold of Indefinite · 744 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗
  • Jul 14, 2015 · D/A · $1,346,181,853 sold of Indefinite · 624 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗
  • Jul 14, 2014 · D/A · $1,142,846,853 sold of Indefinite · 528 investors · min. No minimum reported · role: Executive Officer, Promoter (Member of OrbiMed Advisors) EDGAR ↗
  • Jul 12, 2013 · D/A · $836,672,000 sold of Indefinite · 372 investors · min. No minimum reported · role: Executive Officer, Promoter (Member of OrbiMed Advisors) EDGAR ↗
  • Mar 12, 2013 · D/A · $640,107,000 sold of Indefinite · 299 investors · min. No minimum reported · role: Executive Officer, Promoter (Member of OrbiMed Advisors) EDGAR ↗
  • Mar 12, 2012 · D/A · $446,081,853 sold of Indefinite · 209 investors · min. No minimum reported · role: Executive Officer, Promoter (Member of OrbiMed Advisors) EDGAR ↗
  • Mar 11, 2011 · D/A · $236,139,926 sold of Indefinite · 91 investors · min. No minimum reported · role: Executive Officer, Promoter (Member of OrbiMed Advisors) EDGAR ↗

Raised $1.78B from 880 investors as of the latest filing. Jonathan is listed as executive officer, promoter on 12 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OG
Pooled Investment Fund · group: Orbimed

OrbiMed Global Healthcare Fund, L.P.

New York, NY · Jul 14, 2014 → Jul 16, 2021 · 8 filings
  • Jul 16, 2021 · D/A · $113,350,000 sold of Indefinite · 10 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 16, 2020 · D/A · $113,350,000 sold of Indefinite · 10 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 16, 2019 · D/A · $113,350,000 sold of Indefinite · 10 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 16, 2018 · D/A · $113,350,000 sold of Indefinite · 10 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 14, 2017 · D/A · $113,350,000 sold of Indefinite · 10 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 14, 2016 · D/A · $113,350,000 sold of Indefinite · 10 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 14, 2015 · D/A · $11,250,000 sold of Indefinite · 7 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 14, 2014 · D · $6,000,000 sold of Indefinite · 2 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗

Raised $113.3M from 10 investors as of the latest filing. Jonathan is listed as executive officer on 8 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OG
Pooled Investment Fund · group: Orbimed

OrbiMed Global Healthcare Associates Fund, L.P.

New York, NY · Feb 19, 2014 → Jul 16, 2021 · 9 filings
  • Jul 16, 2021 · D/A · $17,150,000 sold of Indefinite · 7 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 16, 2020 · D/A · $17,150,000 sold of Indefinite · 7 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 16, 2019 · D/A · $17,150,000 sold of Indefinite · 7 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 16, 2018 · D/A · $17,150,000 sold of Indefinite · 7 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 14, 2017 · D/A · $17,150,000 sold of Indefinite · 7 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 14, 2016 · D/A · $17,150,000 sold of Indefinite · 7 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Jul 14, 2015 · D/A · $17,150,000 sold of Indefinite · 7 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Feb 11, 2015 · D/A · $17,150,000 sold of Indefinite · 7 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Feb 19, 2014 · D · $600,000 sold of Indefinite · 2 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗

Raised $17.1M from 7 investors as of the latest filing. Jonathan is listed as executive officer on 9 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ON
Pooled Investment Fund · group: Orbimed

OrbiMed New Horizons Fund, L.P.

New York, NY · Apr 14, 2020 → Apr 14, 2021 · 2 filings
  • Apr 14, 2021 · D/A · $47,325,000 sold of Indefinite · 47 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗
  • Apr 14, 2020 · D · $25,300,000 sold of Indefinite · 10 investors · min. No minimum reported · role: Executive Officer (Member of the Managing Member of the General Partner) EDGAR ↗

Raised $61.6M from 55 investors as of the latest filing. Jonathan is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OA
Pooled Investment Fund · group: Orbimed

OrbiMed Asia Partners IV, L.P.

New York, NY · Mar 5, 2020 → Sep 2, 2020 · 2 filings
  • Sep 2, 2020 · D/A · $486,882,011 sold of $750,000,000 · 86 investors · min. No minimum reported · role: Director (Director of the GPLTD) EDGAR ↗
  • Mar 5, 2020 · D · $0 sold of $750,000,000 · 0 investors · min. No minimum reported · role: Director (Director of the GPLTD) EDGAR ↗

Raised $486.9M from 86 investors (65% of the $750M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OP
Pooled Investment Fund · group: Orbimed

OrbiMed Private Investments VIII, LP

New York, NY · Aug 27, 2020
  • Aug 27, 2020 · D · $0 sold of $1,400,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗

No sales reported yet as of the latest filing. Jonathan is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AB
Biotechnology

Arcutis Biotherapeutics, Inc.

Westlake Village, CA · Oct 22, 2019
  • Oct 22, 2019 · D · $94,499,967 sold of $94,500,000 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $94.5M from 16 investors (100% of the $94.5M target) as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OR
Pooled Investment Fund · group: Orbimed

OrbiMed Royalty & Credit Opportunities III, LP

New York, NY · Jan 29, 2019 → Jul 3, 2019 · 2 filings
  • Jul 3, 2019 · D/A · $889,835,000 sold of $1,200,000,000 · 69 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗
  • Jan 29, 2019 · D · $0 sold of $1,200,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗

Raised $889.8M from 69 investors (74% of the $1.2B target) as of the latest filing. Jonathan is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AB
Biotechnology

Adicet Bio, Inc.

Menlo Park, CA · Aug 26, 2015 → Oct 26, 2018 · 4 filings
  • Oct 26, 2018 · D/A · $25,443,510 sold of $43,318,510 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 27, 2016 · D/A · $25,443,510 sold of $43,318,510 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 27, 2016 · D · $11,313,608 sold of $13,935,086 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 26, 2015 · D · $14,625,000 sold of $40,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $80M from 18 investors (100% of the $43.3M target) as of the latest filing. Jonathan is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

A
Other Health Care

AVEDRO INC

Waltham, MA · May 1, 2017 → May 11, 2018 · 2 filings
  • May 11, 2018 · D · $24,999,971 sold of $24,999,971 · 19 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 1, 2017 · D · $12,000,003 sold of $12,000,003 · 14 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $41.9M from 23 investors (100% of the $25M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OP
Pooled Investment Fund · group: Orbimed

OrbiMed Private Investments VII, LP

New York, NY · Jan 30, 2018
  • Jan 30, 2018 · D · $0 sold of $1,000,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗

No sales reported yet as of the latest filing. Jonathan is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OA
Pooled Investment Fund · group: Orbimed

OrbiMed Asia Partners III, L.P.

New York, NY · Feb 27, 2017 → Sep 6, 2017 · 4 filings
  • Sep 6, 2017 · D/A · $539,960,000 sold of $539,960,000 · 97 investors · min. $100,000 · role: Director (Director of the GPLTD) EDGAR ↗
  • Jun 28, 2017 · D/A · $431,530,000 sold of $450,000,000 · 95 investors · min. No minimum reported · role: Director (Director of the GPLTD) EDGAR ↗
  • Mar 1, 2017 · D/A · $0 sold of $450,000,000 · 0 investors · min. No minimum reported · role: Director (Director of the GPLTD) EDGAR ↗
  • Feb 27, 2017 · D · $0 sold of $450,000,000 · 0 investors · min. No minimum reported · role: Director (Director of the GPLTD) EDGAR ↗

Raised $540M from 97 investors (100% of the $540M target) as of the latest filing. Jonathan is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

N
Other Health Care

NeuroPace Inc

Mountain View, CA · Aug 8, 2017
  • Aug 8, 2017 · D/A · $72,000,001 sold of $80,000,001 · 26 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $72M from 26 investors (90% of the $80M target) as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OP
Pooled Investment Fund · group: Orbimed

OrbiMed Partners, L.P.

New York, NY · Mar 11, 2011 → Jul 14, 2017 · 8 filings
  • Jul 14, 2017 · D/A · $128,115,033 sold of Indefinite · 130 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗
  • Jul 14, 2016 · D/A · $127,850,033 sold of Indefinite · 128 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗
  • Jul 14, 2015 · D/A · $124,585,033 sold of Indefinite · 127 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗
  • Jul 14, 2014 · D/A · $117,935,033 sold of Indefinite · 121 investors · min. No minimum reported · role: Executive Officer, Promoter (Member of OrbiMed Advisors) EDGAR ↗
  • Jul 12, 2013 · D/A · $112,641,000 sold of Indefinite · 119 investors · min. No minimum reported · role: Executive Officer, Promoter (Member of OrbiMed Advisors) EDGAR ↗
  • Mar 12, 2013 · D/A · $111,731,000 sold of Indefinite · 118 investors · min. No minimum reported · role: Executive Officer, Promoter (Member of OrbiMed Advisors) EDGAR ↗
  • Mar 12, 2012 · D/A · $110,685,733 sold of Indefinite · 117 investors · min. No minimum reported · role: Executive Officer, Promoter (Member of OrbiMed Advisors) EDGAR ↗
  • Mar 11, 2011 · D/A · $64,608,125 sold of Indefinite · 50 investors · min. No minimum reported · role: Executive Officer, Promoter (Member of OrbiMed Advisors) EDGAR ↗

Raised $128.1M from 130 investors as of the latest filing. Jonathan is listed as executive officer, promoter on 8 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RP
Pharmaceuticals · group: Rhythm Pharmaceuticals

RHYTHM PHARMACEUTICALS, INC.

Boston, MA · Dec 10, 2015 → Jan 20, 2017 · 2 filings
  • Jan 20, 2017 · D · $20,475,001 sold of $40,949,999 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 10, 2015 · D/A · $40,000,000 sold of $40,000,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $40M from 14 investors (98% of the $40.9M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

S
Pharmaceuticals

scPharmaceuticals Inc.

Lexington, MA · Jan 6, 2017
  • Jan 6, 2017 · D · $46,962,788 sold of $46,962,788 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $47M from 15 investors (100% of the $47M target) as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RB
Biotechnology

Roka BioScience, Inc.

Warren, NJ · Jun 27, 2013 → Sep 30, 2016 · 3 filings
  • Sep 30, 2016 · D · $22,500,000 sold of $22,500,000 · 32 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 5, 2013 · D · $16,996,657 sold of $16,996,657 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 27, 2013 · D · $24,999,999 sold of $24,999,999 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $29.4M from 32 investors (100% of the $22.5M target) as of the latest filing. Jonathan is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

C
Biotechnology

CERAPEDICS INC

Westminster, CO · Mar 30, 2009 → Sep 26, 2016 · 6 filings
  • Sep 26, 2016 · D · $11,000,000 sold of $14,000,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 23, 2015 · D · $4,000,000 sold of $4,000,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 27, 2012 · D/A · $0 sold of $19,090,328 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 20, 2012 · D · $12,090,328 sold of $18,090,328 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 16, 2012 · D · $3,000,000 sold of $3,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 30, 2009 · D · $15,000,000 sold of $15,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $25M from 8 investors (100% of the $14M target) as of the latest filing. Jonathan is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OI
Pooled Investment Fund · group: Orbimed

OrbiMed Israel Partners II, L.P.

New York, NY · Dec 14, 2015
  • Dec 14, 2015 · D · $0 sold of $300,000,000 · 0 investors · min. No minimum reported · role: Executive Officer EDGAR ↗

No sales reported yet as of the latest filing. Jonathan is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AT
Biotechnology

Audentes Therapeutics, Inc.

San Francisco, CA · Dec 24, 2014 → Oct 22, 2015 · 3 filings
  • Oct 22, 2015 · D · $64,999,949 sold of $64,999,949 · 27 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 2, 2015 · D · $0 sold of Indefinite · 21 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 24, 2014 · D · $42,500,002 sold of $42,500,002 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $65M from 27 investors (100% of the $65M target) as of the latest filing. Jonathan is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OP
Pooled Investment Fund · group: Orbimed

OrbiMed Private Investments VI, LP

New York, NY · Sep 15, 2015
  • Sep 15, 2015 · D · $0 sold of $950,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗

No sales reported yet as of the latest filing. Jonathan is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OR
Pooled Investment Fund · group: Orbimed

OrbiMed Royalty Opportunities II, LP

New York, NY · Feb 2, 2015
  • Feb 2, 2015 · D · $900,000,000 sold of $900,000,000 · 83 investors · min. $750,000 · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗

Raised $900M from 83 investors (100% of the $900M target) as of the latest filing. Jonathan is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

D
Other

DFINE INC

San Jose, CA · Jul 15, 2010 → Dec 31, 2013 · 3 filings
  • Dec 31, 2013 · D · $17,487,929 sold of $17,490,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 5, 2011 · D · $14,981,562 sold of $26,500,000 · 16 investors · min. $1 · role: Director EDGAR ↗
  • Jul 15, 2010 · D · $36,165,347 sold of $36,187,884 · 25 investors · min. $1 · role: Director EDGAR ↗

Raised $36.2M from 25 investors (100% of the $17.5M target) as of the latest filing. Jonathan is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OP
Pooled Investment Fund · group: Orbimed

OrbiMed Private Investments V, LP

New York, NY · Nov 5, 2013
  • Nov 5, 2013 · D · $699,500,000 sold of $700,000,000 · 66 investors · min. $150,000 · role: Executive Officer (Member of OrbiMed Advisors) EDGAR ↗

Raised $699.5M from 66 investors (100% of the $700M target) as of the latest filing. Jonathan is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OA
Pooled Investment Fund · group: Orbimed

OrbiMed Asia Partners II, LP

New York, NY · Aug 15, 2013
  • Aug 15, 2013 · D · $0 sold of $300,000,000 · 0 investors · min. No minimum reported · role: Director (Director of the general partner of the general partner of the Issuer) EDGAR ↗

No sales reported yet as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

GC
Other Health Care · group: Group linked by Olav B. Bergheim

GLAUKOS Corp

Laguna Hills, CA · Sep 23, 2010 → Jan 25, 2013 · 5 filings
  • Jan 25, 2013 · D · $30,000,002 sold of $30,000,002 · 20 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 3, 2012 · D · $6,000,000 sold of $6,000,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 10, 2012 · D · $4,500,000 sold of $4,500,000 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 1, 2011 · D · $29,500,003 sold of $29,500,003 · 18 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 23, 2010 · D · $6,000,392 sold of $6,000,392 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $30M from 20 investors (100% of the $30M target) as of the latest filing. Jonathan is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

R
Pharmaceuticals

Relypsa Inc

Santa Clara, CA · Sep 14, 2010 → Dec 11, 2012 · 5 filings
  • Dec 11, 2012 · D/A · $65,000,192 sold of $80,000,200 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 5, 2012 · D/A · $62,412,304 sold of $80,000,200 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 10, 2012 · D · $49,677,652 sold of $80,000,200 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 8, 2011 · D/A · $70,129,747 sold of $70,129,747 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 14, 2010 · D · $35,129,747 sold of $70,129,747 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $70.1M from 15 investors (88% of the $80M target) as of the latest filing. Jonathan is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

IP
Biotechnology

INTERCEPT PHARMACEUTICALS INC

New York, NY · Aug 24, 2012 → Sep 4, 2012 · 2 filings
  • Sep 4, 2012 · D/A · $30,000,000 sold of $50,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 24, 2012 · D · $15,000,000 sold of $30,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $30M from 2 investors (60% of the $50M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

EP
Biotechnology

Enobia Pharma Corp

Montreal, Quebec, Canada (as filed: A8) · Aug 28, 2009 → Aug 24, 2011 · 4 filings
  • Aug 24, 2011 · D · $20,000,000 sold of $40,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 1, 2011 · D · $15,000,000 sold of $46,969,070 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 13, 2010 · D/A · $50,000,000 sold of $50,000,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 28, 2009 · D · $15,000,000 sold of $50,000,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $50M from 8 investors (100% of the $40M target) as of the latest filing. Jonathan is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

OI
Pooled Investment Fund · group: Orbimed

OrbiMed Israel Partners Limited Partnership

Tel Aviv, Israel (as filed: L3) · Apr 18, 2011
  • Apr 18, 2011 · D · $190,375,000 sold of Indefinite · 50 investors · min. No minimum reported · role: Executive Officer EDGAR ↗

Raised $190.4M from 50 investors as of the latest filing. Jonathan is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

CP
Pooled Investment Fund · group: Orbimed

Caduceus Private Investments IV, LP

New York, NY · Dec 30, 2009
  • Dec 30, 2009 · D · $312,364,000 sold of $550,000,000 · 29 investors · min. No minimum reported · role: Executive Officer, Promoter (Member of OrbiMed Advisors) EDGAR ↗

Raised $312.4M from 29 investors (57% of the $550M target) as of the latest filing. Jonathan is listed as executive officer, promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (3)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

People around Jonathan 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

OA
Management entity

OrbiMed Advisors LLC

Executive Officer, Promoter · 50 shared filings (13 issuers) · also on 9 other issuers

OrbiMed Advisors LLC is on 22 issuers in total — a repeat sponsor. Their page lists every one.

OG
Management entity

OrbiMed Global Healthcare GP LLC

Executive Officer · 17 shared filings (2 issuers)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OA
Management entity

OrbiMed Asia GP III, L.P.

Executive Officer, Promoter · 4 shared filings (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OA
Management entity

OrbiMed Advisors III Limited

Executive Officer, Promoter · 4 shared filings (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OG
Management entity

OrbiMed Genesis GP LLC

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OR
Management entity

OrbiMed ROF III LLC

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OA
Management entity

OrbiMed Asia GP IV, L.P.

Executive Officer, Promoter · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OA
Management entity

OrbiMed Advisors IV Limited

Executive Officer, Promoter · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

ON
Management entity

OrbiMed New Horizons GP LLC

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OC
Management entity

OrbiMed Capital GP IV LLC

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OI
Management entity

OrbiMed Israel GP, Limited

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OA
Management entity

OrbiMed Advisors II Limited

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OA
Management entity

OrbiMed Asia GP II, L.P.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OC
Management entity

OrbiMed Capital GP V LLC

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OR
Management entity

OrbiMed ROF II LLC

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OC
Management entity

OrbiMed Capital GP VI LLC

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OI
Management entity

OrbiMed Israel GP II, L.P.

Executive Officer, Promoter · 1 shared filing (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OA
Management entity

OrbiMed Advisors Israel II Limited

Executive Officer, Promoter · 1 shared filing (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OC
Management entity

OrbiMed Capital GP VII LLC

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OC
Management entity

OrbiMed Capital GP VIII LLC

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Carl L. Gordon

Executive Officer, Promoter, Director · 63 shared filings (19 issuers) · also on 43 other issuers

Carl L. Gordon is on 62 issuers in total — a repeat sponsor. Their page lists every one.

WN
No photo found yet (own website and image search run after this page is viewed)
Person

W. Carter Neild

Executive Officer, Promoter, Director · 58 shared filings (17 issuers) · also on 8 other issuers

W. Carter Neild is on 25 issuers in total — a repeat sponsor. Their page lists every one.

SB
No photo found yet (own website and image search run after this page is viewed)
Person

Sven H. Borho

Executive Officer, Promoter, Director · 55 shared filings (15 issuers) · also on 12 other issuers

Sven H. Borho is on 27 issuers in total — a repeat sponsor. Their page lists every one.

GH
No photo found yet (own website and image search run after this page is viewed)
Person

Geoffrey C. Hsu

Executive Officer, Promoter · 49 shared filings (12 issuers) · also on 6 other issuers

Geoffrey C. Hsu is on 18 issuers in total — a repeat sponsor. Their page lists every one.

SI
No photo found yet (own website and image search run after this page is viewed)
Person

Samuel D. Isaly

Executive Officer, Promoter, Director · 36 shared filings (12 issuers) · also on 7 other issuers

Samuel D. Isaly is on 19 issuers in total — a repeat sponsor. Their page lists every one.

CS
No photo found yet (own website and image search run after this page is viewed)
Person

C. Scotland Stevens

Executive Officer · 15 shared filings (6 issuers) · also on 6 other issuers

C. Scotland Stevens is on 12 issuers in total — a repeat sponsor. Their page lists every one.

DB
No photo found yet (own website and image search run after this page is viewed)
Person

David P. Bonita

Director, Executive Officer · 14 shared filings (7 issuers) · also on 21 other issuers

David P. Bonita is on 28 issuers in total — a repeat sponsor. Their page lists every one.

TS
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas Schuetz

Director · 12 shared filings (3 issuers)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

MS
No photo found yet (own website and image search run after this page is viewed)
Person

Michael B. Sheffery

Executive Officer, Promoter · 10 shared filings (4 issuers)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

GK
No photo found yet (own website and image search run after this page is viewed)
Person

Gilbert H. Kliman

Director · 7 shared filings (2 issuers) · also on 5 other issuers

Gilbert H. Kliman is on 7 issuers in total — a repeat sponsor. Their page lists every one.

AT
No photo found yet (own website and image search run after this page is viewed)
Person

Andrew J. Tofe

Director · 6 shared filings (1 issuer)

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

CK
No photo found yet (own website and image search run after this page is viewed)
Person

Chau Khuong

Director · 6 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

DW
No photo found yet (own website and image search run after this page is viewed)
Person

David G. Wang

Executive Officer, Director · 6 shared filings (2 issuers) · also on 5 other issuers

David G. Wang is on 7 issuers in total — a repeat sponsor. Their page lists every one.

SS
No photo found yet (own website and image search run after this page is viewed)
Person

Sunny Sharma

Executive Officer, Director · 6 shared filings (2 issuers) · also on 2 other issuers

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

OB
No photo found yet (own website and image search run after this page is viewed)
Person

Olav B. Bergheim

Director, Executive Officer · 5 shared filings (1 issuer) · also on 13 other issuers

Olav B. Bergheim is on 14 issuers in total — a repeat sponsor. Their page lists every one.

WL
No photo found yet (own website and image search run after this page is viewed)
Person

William Link

Director · 5 shared filings (1 issuer) · also on 28 other issuers

William Link is on 29 issuers in total — a repeat sponsor. Their page lists every one.

SR
No photo found yet (own website and image search run after this page is viewed)
Person

Scott Rocklage

Director · 5 shared filings (1 issuer) · also on 17 other issuers

Scott Rocklage is on 18 issuers in total — a repeat sponsor. Their page lists every one.

GK
No photo found yet (own website and image search run after this page is viewed)
Person

Gerrit Klaerner

Executive Officer, Director · 5 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Jonathan T. Silverstein. Their page shows their other deals.

RH
No photo found yet (own website and image search run after this page is viewed)
Person

Richard Harrison

Executive Officer · 5 shared filings (1 issuer) · also on 4 other issuers

Richard Harrison is on 5 issuers in total — a repeat sponsor. Their page lists every one.

The team behind the deals

O
Sponsor group

Orbimed

37 issuers · 166 filings · $20.2B reported sold · 2009–2026

One team, 37 deal companies. Jonathan T. Silverstein is listed on 19 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Jonathan T. Silverstein.

RP
Sponsor group

Rhythm Pharmaceuticals

3 issuers · 8 filings · $54M reported sold · 2010–2017

One team, 3 deal companies. Jonathan T. Silverstein is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Jonathan T. Silverstein.

GL
Sponsor group

Group linked by Olav B. Bergheim

14 issuers · 55 filings · $144.9M reported sold · 2008–2025

One team, 14 deal companies. Jonathan T. Silverstein is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Jonathan T. Silverstein.

Same business address

51 other issuers file from the same address (first 50 shown)

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

A person is never an adviser firm. 13 of the 33 issuers this person is listed on match a Form ADV adviser (searched 24,962 advisers as of Oct 2, 2026): OrbiMed Partners II, L.P., OrbiMed Genesis Fund, L.P., OrbiMed New Horizons Fund, L.P., OrbiMed Global Healthcare Associates Fund, L.P., OrbiMed Global Healthcare Fund, L.P., OrbiMed Private Investments VIII, LP, OrbiMed Royalty & Credit Opportunities III, LP, OrbiMed Private Investments VII, LP, OrbiMed Partners, L.P., OrbiMed Private Investments VI, LP, OrbiMed Royalty Opportunities II, LP, OrbiMed Private Investments V, LP, Caduceus Private Investments IV, LP.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Jonathan T. Silverstein by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 33 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Jonathan T. Silverstein is listed on: none on file. No website or social profile named in OrbiMed Royalty Opportunities II, LP's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #308,301 of 374,652 in line (14 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (New York, NY). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗New York WebCivil Supreme ↗California — find the county court ↗Los Angeles Superior Court case search ↗New Jersey state courts — find the court ↗Colorado state courts — find the court ↗Massachusetts MassCourts ↗Cook County Clerk of Court case search ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

New York Secretary of State business search ↗California Secretary of State business search ↗New Jersey Secretary of State business search ↗Colorado Secretary of State business search ↗Massachusetts Secretary of State business search ↗Illinois Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Jonathan T. Silverstein appears on a new Form D, or when a court case or SEC action is matched to them. See plans →